List view / Grid view
2 March 2016 | By Victoria White
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections...
16 October 2015 | By Victoria White
The trials will evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of acute bacterial skin and skin structure infections...
3 September 2015 | By Victoria White
The FDA has granted Fast Track designation to iclaprim to treat acute bacterial skin and skin structure infections and hospital acquired bacterial pneumonia...
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
